Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016', provides in depth analysis on Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
- The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Overview 7
Therapeutics Development 8
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Stage of Development 8
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Therapy Area 9
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Indication 10
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Companies 13
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Universities/Institutes 15
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development 22
Advinus Therapeutics Ltd 22
Amgen Inc. 23
Astellas Pharma Inc. 24
Caldan Therapeutics Limited 25
Connexios Life Sciences Pvt. Ltd. 26
Daiichi Sankyo Company, Limited 27
Hyundai Pharmaceutical Co., Ltd. 28
Japan Tobacco Inc. 29
Jiangsu Hengrui Medicine Co., Ltd. 30
Merck & Co., Inc. 31
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles 32
AM-1638 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AM-3189 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AM-6226 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
AS-2034178 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
AS-2575959 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CNX-01167 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DS-1558 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
HD-6277 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
JTT-851 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
MK-8666 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Antagonize GPR40 for Obesity - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Agonize GPR40 for Diabetes - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TUG-770 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Projects 47
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products 48
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Featured News & Press Releases 49
Apr 10, 2012: Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU -CEO 49
Jun 27, 2011: Connexios Life Science Presents Preclinical Data On CNX-011-67 At American Diabetes Association Meeting 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Advinus Therapeutics Ltd, H2 2016 22
Pipeline by Amgen Inc., H2 2016 23
Pipeline by Astellas Pharma Inc., H2 2016 24
Pipeline by Caldan Therapeutics Limited, H2 2016 25
Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 26
Pipeline by Daiichi Sankyo Company, Limited, H2 2016 27
Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 28
Pipeline by Japan Tobacco Inc., H2 2016 29
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 30
Pipeline by Merck & Co., Inc., H2 2016 31
Dormant Projects, H2 2016 47
Discontinued Products, H2 2016 48